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Key points: 
 There is evidence that patients’ health-related quality of life (HRQL) improves in the 
6 months after a first appointment at a memory assessment service (MAS), but the 
sustainability of such benefits is unknown. 
 In a large multi-centre study of 702 patients, we show that improvements in HRQL 
are maintained up to one year after the first appointment. 
 The largest improvements are observed in those patients who receive a diagnosis of 
dementia. 
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ABSTRACT 
Objectives: Our group has already demonstrated that patients’ health-related quality of life 
(HRQL) improves in the first 6 months after their first appointment at memory assessment 
services (MASs), but the sustainability of such gains is unknown. We aimed to describe 
changes in patients’ HRQL at 12 months after their first MAS appointment and to examine 
associations with patient and MAS characteristics.  
Methods: We collected data from 702 patients and 452 lay caregivers at the first 
appointment and 12 months later. Multivariable linear regression was used to examine the 
relationships of change in HRQL (self- and proxy-reported) with patients’ characteristics and 
use of post-diagnostic interventions, and multilevel models were used to analyse the 
relationships of HRQL with MAS characteristics.  
Results: In the whole group, self-reported HRQL improved over 12 months (+3.5 points, 95% 
CI 2.7 to 4.2). Among people diagnosed with dementia, improvement in HRQL was more 
than double that among those with mild cognitive impairment or no diagnosis. Proxy-
reported HRQL improved only in those diagnosed with dementia (+1.2 points, 95% CI 0.2 to 
2.2). Changes in HRQL were not associated with any patient characteristics. The only feature 
of MASs associated with larger improvements in HRQL was the presence of advisory and 
support staff.  
Conclusions: Improvements in HRQL observed at 6 months are maintained up to one year 
after the first MAS appointment, more so among those who receive a diagnosis of 
dementia. Continued follow up will determine if the improvement is even longer lasting.  
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INTRODUCTION 
Memory assessment services (MASs) have a central role in dementia care, providing 
assessment and diagnosis for new referrals, post-diagnostic support, and follow-up.1-4 The 
past decade has seen a significant increase in provision of, and investment in, these 
services.5  
Despite rapid expansion in service provision, evidence for the benefits of MASs in terms of 
patient outcomes is limited.6 It is only recently that robust evaluation of the effectiveness of 
MASs has emerged. The largest published study of MAS patients to date, which followed up 
nearly 900 patients from a nationally representative sample of clinics across England, found 
that patients’ health-related quality of life (HRQL) improves in the first six months after their 
first appointment at a MAS.7 This finding is consistent with earlier small-scale studies, which 
suggested that MASs may be beneficial in the initial months after referral.8,9 However, 
evidence for patient outcomes beyond six months is currently lacking so the sustainability of 
such benefits is not known. It is also unknown whether any patient characteristics, use of 
anti-dementia drugs or psychosocial interventions, or characteristics of the MASs have an 
impact on outcomes beyond six months.  
The aims of this study were: [1] to describe the change in patients’ HRQL over the first 12 
months after the first MAS appointment; [2] to examine whether patient characteristics are 
associated with changes in HRQL; [3] to determine if the use of anti-dementia drugs and/or 
psychosocial interventions is associated with improved HRQL in those patients diagnosed 
with dementia; and [4] to investigate the extent to which characteristics of MASs are 
associated with patients’ HRQL at 12 months. 
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METHODS 
Sample 
We randomly selected 80 MASs from all 212 clinics in England identified in the Royal College 
of Psychiatrists national audit.5 Of these, 73 MASs took part in the study at baseline (2 sites 
did not participate, 5 sites recruited fewer than 6 patients each and were excluded) and 71 
remained in the study at 12-month follow up. The selected MASs were representative of all 
clinics in England in terms of patient volume, waiting times and accreditation status.5  
Patients referred for a first appointment between September 2014 and April 2015 with 
sufficient English language to understand the consent process and questionnaires, and their 
informal caregivers, were eligible for inclusion. Each site was asked to recruit up to 25 
consecutive new patients.10  
Questionnaires were completed by patients (interviewer administered) and their caregivers 
(self-administered) at the time of the first appointment (before diagnosis) and 12 months 
later.  Additionally at baseline, all 71 MASs completed organisational questionnaires on their 
structural and process characteristics.11  
Outcomes 
The patient questionnaires at baseline and 12 months included measures of disease-specific 
(DEMQOL12) and generic (EQ-5D-3L13) HRQL. DEMQOL is a 28-item instrument with items 
scored on a four-point response scale, with higher score indicating better HRQL. We used a 
scoring algorithm based on Rasch Measurement Theory to generate scores,14 and for 
analysis the scores were linearly transformed to range from 0 to 100. The EQ-5D-3L has five 
items, each covering one domain: mobility, self-care, usual activities, pain/discomfort and 
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anxiety/depression. A summary EQ-5D-3L index score was calculated using value sets 
derived from a UK general population survey to weight and combine responses.15 Informal 
caregivers completed proxy-reported instruments for assessing the disease specific 
(DEMQOL-Proxy14) and generic (EQ-5D-3L proxy15) HRQL of the patient.   
The primary outcomes in this study were changes in patients’ DEMQOL and DEMQOL-Proxy 
scores between first appointment (baseline) and 12 month follow up. We also included self- 
and proxy-reported EQ-5D-3L index scores as secondary outcomes. 
Patient-level characteristics 
Data on patients' socio-demographic characteristics (age; sex; ethnicity; socio-economic 
status based on patients’ residential postcodes and quintiles of the national ranking of Index 
of Multiple Deprivation IMD scores16) were collected at baseline.  
At each time point, interviewers extracted data from the patient's case notes on whether 
the patient had any comorbid conditions from a pre-specified list (heart disease, high blood 
pressure, problems caused by stroke, leg pain due to poor circulation, lung disease, 
diabetes, kidney disease, diseases of the nervous system, liver disease, cancer within the 
last 5 years, depression or arthritis).17 At baseline, data on cognitive function were extracted 
and used to derive a three-category cognitive function variable based on tertiles from our 
own data on the Mini-Mental State Examination (MMSE) score18: category 1 (lowest 
cognitive function) equivalent to MMSE score <24, category 2 MMSE score 24-27, and 
category 3 (highest cognitive function) MMSE score ≥28. The threshold for the lowest tertile 
(<24) corresponds to that often used in screening for dementia.19 At 12-month follow up, 
interviewers extracted information on patient diagnosis (categorised as: dementia; mild 
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cognitive impairment MCI; other diagnosis; no diagnosis reached or not thought to have any 
cognitive impairment).  
Informal caregivers provided information on anti-dementia drugs the patient had been 
prescribed and psychosocial interventions they had received since their first appointment. 
Respondents were asked to select psychosocial interventions from a predetermined list 
including cognitive behaviour therapy, music therapy, animal assisted therapies, social 
engagement groups, walking groups, life story work, peer support groups, befriending 
services, memory cafes and reminiscence therapy, in addition to providing free-text 
information on any interventions that were not listed.  
MAS characteristics 
Structural and process characteristics which varied between MASs were selected for 
analysis,11 with dementia policy experts, clinicians, researchers and a lay advisory group 
involved in the final selection. Structural variables were: skill mix (presence of clinical 
psychologists, allied health professionals, and advisory and support staff), number of new 
patients per whole time equivalent (WTE) staff per month, number of new patients seen by 
the MAS each month, provision of clinical assessments (at first appointment: ECG, 
neurological examination; at follow up: physical examination, vision/hearing/mobility 
assessment) and a structural measure of the provision of post-diagnostic psychosocial 
interventions.  
Process characteristics were: waiting time to first appointment (categorised as ≤6 or >6 
weeks, the recommended standard20), length of first appointment, and number of follow-up 
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appointments within the first year (categorised as ≤1 or >1, i.e. clinic follow-up complete by 
12 months or ongoing). 
Statistical analysis 
Patient and MAS characteristics were summarised as means and standard deviations (SDs) 
or percentages. We used chi-squared tests to compare the characteristics of respondents at 
12 months with those of non-respondents. Change in each measure of HRQL was assessed 
using paired t-tests to compare mean scores at baseline and 12 months, for the whole 
sample of patients and by diagnosis. 
We used multivariable linear regression to examine the relationships between patient 
characteristics and change in HRQL at 12 months, adjusting for all patient characteristics and 
HRQL score at baseline. Clustering of patients within MASs was taken into account using 
cluster-robust standard errors. In the sub-group of patients diagnosed with dementia, linear 
regression was used to assess the relationships between use of anti-dementia drugs and 
psychosocial interventions and change in HRQL, adjusting for patient characteristics, 
cognitive function and HRQL at baseline, and in the case of anti-dementia drugs adjusting 
for psychosocial interventions and vice versa. Due to the clustering of use of psychosocial 
interventions (differences in use between sites), we adjusted for MAS as a random effect. 
Results of linear regression models are presented as adjusted differences in HRQL change 
score with confidence intervals CIs.  
Multilevel linear regression models were used to examine the relationships between MAS 
characteristics and patient HRQL at 12 months. Models included all structural and process 
characteristics, and were adjusted for patient-level variables and MAS as a random effect. 
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Analyses were conducted on the full sample of patients, and on the sub-sample of patients 
diagnosed with dementia. We report results as adjusted differences in HRQL score with 
confidence intervals.  
Due to the large number of tests conducted and associated risk of Type I errors, in the 
analyses of patient and MAS characteristics we applied the Bonferroni adjustment for 
multiple testing to p-values (family-wise error rate of 0.05 per model divided by the number 
of tests k; in analysis of patient characteristics k = 12, in analysis of MAS characteristics 
k=17). Although the risk of missing a possible association (Type II error) is increased, this 
approach allows a greater degree of certainty about any effects that are observed.21 
All analyses were conducted using Stata V.14 (StataCorp, College station, Texas, USA). 
Ethical approval 
The study protocol was approved by the National Research Ethics Service Committee 
London (reference: 14/LO/1146) and the London School of Hygiene & Tropical Medicine 
ethics committee (reference: 8418). 
RESULTS 
Sample characteristics 
Of the 1346 patients and 970 caregivers eligible for follow up, 702 (52%) patients and 452 
(47%) caregivers completed questionnaires at 12 months (Supplementary Figure 1). The 
mean time to follow up was 12.8 months (SD 1.0), with 95% of participants followed up 
between 10 and 15 months. Participants who were followed up late (>15 months from 
baseline) were similar to other participants in regards age, sex, ethnicity, deprivation, 
cognitive function, number of comorbidities, and HRQL at baseline. The only difference was 
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a higher proportion had an informal caregiver participate at baseline (94% versus 71%, 
p=0.006).  
The characteristics of study participants are summarised in Table 1. Respondents at 12 
months were similar to non-respondents in terms of ethnicity, deprivation, comorbidities, 
HRQL scores at baseline and diagnosis, but were slightly younger (mean age 77.3 versus 78.6 
years), more likely to be male (52% versus 44% male) and had higher cognitive function at 
baseline (31% versus 26% in highest cognitive function category).  
[Insert Table 1 here] 
By 12 months after the first MAS appointment, 59% (n=405) of patients had received a 
diagnosis of dementia, and 26% (n=182) had received a diagnosis of mild cognitive 
impairment (MCI). A few (4%, n=28) had a psychiatric, cerebrovascular (no dementia) or 
trauma-related diagnosis, and 11% (n=75) had received no diagnosis, some of whom had no 
evidence of cognitive impairment at baseline.  
Change in HRQL over first 12 months 
Between baseline and 12 months, self-reported HRQL (DEMQOL) in the whole study 
population increased by 3.5 points (95% CI 2.7 to 4.3) (effect size: 0.29 SD) (Table 2). While 
all diagnostic groups demonstrated an increase in HRQL, this increase was larger among 
those with a diagnosis of dementia (+4.8 points, 95% CI 3.8 to 5.9; effect size: 0.40 SD) than 
those with MCI (+1.9, 95% CI 0.6 to 3.2; effect size: 0.16 SD) or no diagnosis (+1.6, 95% CI -
0.6 to 3.9; effect size: 0.13 SD). No change in self-reported generic HRQL (EQ-5D-3L) was 
detected.  
[Insert Table 2 here] 
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Although proxy-reported HRQL (DEMQOL-Proxy) for the whole sample did not change over 
12 months, the mean score did increase in the sub-group of those with a diagnosis of 
dementia (+1.2, 95% CI 0.2 to 2.2; effect size 0.13 SD).  
There was no change in proxy-reported EQ-5D-3L index score except among those with a 
diagnosis of MCI in whom it decreased slightly (-0.05, 95% CI -0.1 to -0.008; effect size: 0.17 
SD). 
Patient characteristics and change in HRQL 
Changes in self- and proxy-reported HRQL (DEMQOL and DEMQOL-Proxy) were not 
associated with any of the patient characteristics in adjusted analyses (Table 3). This was 
also the case with generic measures of HRQL (self- and proxy-reported EQ-5D-3L index 
scores; results not presented). 
[Insert Table 3 here] 
Associations between change in HRQL and interventions in patients with dementia 
Of the patients with dementia and data on intervention use (of any kind), 183 (63%) had 
been prescribed anti-dementia drugs since receiving their diagnosis and 97 (33%) had used 
psychosocial interventions. Of these, 63 (22%) received both types of intervention. The 
HRQL of patients with dementia improved regardless of whether or not they received 
interventions (Table 4). For both anti-dementia drugs and psychosocial interventions the 
improvements were larger among those using the interventions than those not, though the 
differences were not statistically significant: the DEMQOL score for those prescribed anti-
dementia drugs increased over 12 months by 6.0 points, compared with 3.4 points among 
those not prescribed these drugs (p-value from Z-test = 0.06); and by 6.6 points among 
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those using psychosocial interventions compared with 4.3 points among those not (p-value: 
0.34). No interaction effect between anti-dementia drugs and psychosocial intervention was 
detected.  
[Insert Table 4 here] 
MAS characteristics and patients’ HRQL at 12 months 
In the whole sample of patients, self-reported HRQL was not associated with any MAS 
characteristics in the adjusted analysis (Table 5).  
[Insert Table 5 here] 
Among those participants who received a diagnosis of dementia, only one MAS 
characteristic was associated with change in HRQL: the presence of advisory and support 
staff (support workers, social workers, mental health workers, dementia advisers) in the 
multi-professional team was associated with larger improvement in self-reported HRQL 
(DEMQOL score +4.3 points, 95% CI 0.9 to 7.8) (Table 5).  
MAS characteristics were not associated with changes in proxy-reported HRQL or with self- 
and proxy-reported generic measures of HRQL in adjusted analyses (results available as 
Supplementary Table 1). This was true both for the overall sample and among those with a 
diagnosis of dementia (Supplementary Table 2). 
DISCUSSION 
Main findings 
One year after their first MAS appointment, the majority of patients had received a 
diagnosis of either dementia or MCI. For the whole sample of patients, the improvements in 
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self-reported dementia-specific HRQL previously observed at 6 months were still evident at 
12 months. We did not find improvements in generic HRQL measured using EQ-5D, but such 
generic measures often have poor construct validity among people with dementia and the 
use of condition-specific measures is recommended.22  
Self-reported improvement in dementia-specific HRQL among those patients diagnosed with 
dementia was more than twice that among those with MCI or no diagnosis. Although a small 
improvement in proxy-reported HRQL was observed among those with dementia, this was 
not apparent in those without a diagnosis of dementia. The improvement among those 
diagnosed with dementia was greater in those treated with anti-dementia drugs or using 
psychosocial interventions, though these associations did not reach statistical significance at 
the 5% level.  
There were no associations between structural characteristics of MASs and outcomes apart 
from, among those with dementia, the inclusion of advisory and support staff which was 
associated with larger improvements in self-reported HRQL. None of the process 
characteristics studied were associated with the outcomes.  
Strengths and limitations 
This is the largest study of changes in HRQL among people referred to MASs. The selected 
MASs are representative of all services in England, and at baseline the sample was largely 
representative of all patients attending them.10  
The study has four limitations. First, due to the absence of a control arm (of people with 
suspected dementia who were not referred to MASs), it is not possible to attribute the 
improvement in HRQL to attending a MAS. As there is a lack of clinical equipoise about the 
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value of early intervention for dementia, it is not ethical to randomise people to delayed 
referral, and consequently data on the natural history of HRQL (without any intervention) 
are not available. However, longitudinal studies assessing HRQL of people with dementia 
(using dementia-specific measures of HRQL) generally report no mean change in self-
reported HRQL and no change or a decline in proxy-reported HRQL over periods of up to 
three years.23-29 
Second, the recruitment rate at baseline was 42%, and only half of participants responded 
at 12 months. Participants recruited into the study at baseline were slightly younger, more 
likely to be male and had slightly better cognitive function when compared with referrals 
who did not take part.10 At follow-up, only three of 12 characteristics differed between 
respondents and non-respondents, and of those three only cognitive function at baseline 
was associated with changes in HRQL. However, our analyses and previous studies indicate 
that better cognitive function at baseline is associated with a decrease in self-reported 
HRQL,23 therefore given the higher proportion of respondents with mild impairment 
(MMSE>27) in our sample, any bias is likely to have led to a slight under- rather than over-
estimate of the extent of improvement in self-reported HRQL.    
Third, there may have been other patient factors associated with outcomes, which were not 
fully accounted for in our analyses of intervention use. For example, the presence of 
contraindications to commonly used anti-dementia drugs. 
Fourth, in our analysis of MAS characteristics, some were difficult to standardise across 
services despite our efforts to verify responses via telephone follow up (e.g. WTE staff levels 
as individuals worked across multiple services). In addition, some data were based on staff’s 
estimates of typical or mean values (e.g. waiting time).  
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Comparison with other studies 
Data from the same cohort of MAS attendees showed that patients’ self-reported HRQL 
increased by 3.4 points (0.28 SD) over the first 6 months from first appointment.7 The 
current study shows that this improvement in HRQL is still evident after 12 months (3.5 
points). While the improvement in HRQL at six months had been the same across all 
diagnostic groups, at 12 months there was a larger improvement among those with 
dementia. That might suggest that the current design of MASs is only of benefit (as 
measured in terms of dementia-specific HRQL) to those with MCI for the initial six months. 
Consistent with other longitudinal studies of people with dementia, we found that changes 
in HRQL were not associated with patients’ socio-demographic characteristics at 
baseline.24,26,28,30,31 One study reported declines in HRQL to be associated with the number 
of comorbidities,32 but this was in a population of older adults in care homes, who had 
poorer general health than participants in our study.  
Analysis of 6 month data had found that patients with dementia who received anti-
dementia drugs reported that their HRQL was improved by 4.6 points on average (compared 
with 2.2 in the non-treated group).7 At 12 months this difference was still apparent but was 
not statistically significant due to the smaller sample size as a result of attrition.  
As regards the impact of psychosocial interventions, the negative association detected at 6 
months (change in DEMQOL score 2.4 points, compared with 3.8 in non-treated group) was 
no longer apparent at 12 months.  The lack of a negative association at 12 months might 
indicate that the benefits of psychosocial interventions occur sometime after the initial 
diagnosis. This would be consistent with some qualitative studies which concluded that in 
people with early-stage dementia, confronting the challenges of memory loss can lead to 
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despair and a struggle with acceptance of a diagnosis.33 In addition, early interactions with 
professional staff can contribute to feelings of loss of autonomy: in a study of men with 
early-stage Alzheimer’s Disease, the majority of participants described initially perceiving 
outside help as another symbol of the many losses associated with their diagnosis.34 The 
same study described a longer-term and ongoing process of reconstructing a sense of self.  
The positive effect of allied health professional staff on HRQL at 6 months35 was no longer 
apparent  at 12 months. However, this had been replaced by the apparent benefit of 
advisory and support staff at 12 months which lends weight to the idea that the benefits of 
different interventions vary over the course of a patient’s journey following diagnosis. 
Implications 
Improvements in HRQL observed in the first 6 months are maintained up to one year after 
the first MAS appointment, more so among those who receive a diagnosis of dementia. 
Although this study cannot establish causality, these findings may point to the potential 
value of early assessment, diagnosis and intervention in people with dementia. The likely 
value of MAS for people with MCI is less clear, but this may reflect the dementia specific 
outcomes used in this study. Longer-term follow up is needed to determine the 
sustainability of any improvements and to establish the cost-utility of MASs. Research to 
describe the trajectories of HRQL among different groups of patients, for example by type 
and severity of dementia, and over a greater number of time points could help to identify 
important transition stages in dementia which may inform the targeting of psychosocial 
interventions.  
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Table 1: Characteristics of respondents and non-respondents at 12 months 
Patient characteristic Respondents Non-respondents p-value from 
χ2 test 
Mean age (years) 77.3 (SD 8.3) 78.6 (SD 8.5) 0.004 * 
% female 340 (48.4%) 389 (55.7%) 0.007 * 
Black, Asian or minority ethnic (BAME) 33 (4.7%) 38 (5.5%) 0.530 
     Missing 4 4  
Deprivation quintile    
     1 – least deprived 186 (26.8%) 161 (23.4%) 0.079 
     2 163 (23.5%) 134 (19.5%)  
     3 129 (18.6%) 148 (21.5%)  
     4 123 (17.7%) 129 (18.8%)  
     5 – most deprived 93 (13.4%) 115 (16.7%)  
     Missing 8 12  
Cognitive function at baseline    
     Lowest MMSE<24 205 (37.1%) 256 (46.8%) 0.005 * 
     MMSE 24-27 175 (31.7%) 150 (27.4%)  
     Highest MMSE >27 173 (31.3%) 141 (25.8%)  
     Missing 149 152  
Number of comorbidities at baseline    
     None 149 (21.3%) 162 (23.2%) 0.420 
     1 199 (28.4%) 172 (24.6%)  
     2 157 (22.4%) 167 (23.9%)  
     3 or more 195 (27.9%) 197 (28.2%)  
     Missing 2 1  
Companion in study at baseline 509 (72.5%) 498 (71.2%) 0.599 
Diagnosis at 12 months     
     Dementia 405 (58.7%) N/A N/A 
     MCI 182 (26.4%) N/A  
     Other 28 (4.0%) N/A  
     No diagnosis took place 75 (10.9%) N/A  
     Missing 12 N/A  
Patient HRQL at baseline    
EQ-5D-3L Index (self report) 0.71 (SD 0.28) 0.71 (SD 0.27) 0.845 
EQ-5D-3L Index (proxy report) 0.62 (SD 0.30) 0.60 (SD 0.30) 0.396 
DEMQOL (equated score, standardised) 65.5 (SD 12.2) 64.5 (SD 12.1) 0.132 
DEMQOL-Proxy (equated score, standardised) 57.0 (SD 9.2) 55.9 (SD 9.8) 0.053 
HRQL – health-related quality of life; MCI – mild cognitive impairment; MMSE – Mini Mental State 
Examination; * - indicates statistically significant difference at 5% level.  
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Table 2: Change in patient health-related quality of life, in all participants and by diagnosis at 12 
months  
 Score at baseline 
Mean (SD) 
Score at 12 
months 
(Mean SD) 
Mean change (95% 
CI) 
DEMQOL equated score (n=694) 65.5 (12.2) 69.0 (13.2) 3.5 (2.7 to 4.3) 
Dementia (n=397) 66.1 (12.5) 71.0 (13.7) 4.8 (3.8 to 5.9) 
MCI (n=182) 66.5 (11.5) 68.4 (12.4) 1.9 (0.6 to 3.2) 
No diagnosis (n=75) 62.8 (12.3) 64.4 (10.7) 1.6 (-0.6 to 3.9) 
EQ-5D-3L index score (n=681) 0.71 (0.28) 0.72 (0.29) 0.01 (-.005 to .03) 
Dementia (n=392) 0.74 (0.25) 0.75 (0.3) 0.01 (-.02 to .04) 
MCI (n=176) 0.70 (0.29) 0.72 (0.29) 0.02 (-.02 to .05) 
No diagnosis (n=74) 0.64 (0.30) 0.67 (0.30) 0.03 (-.03 to 0.1) 
DEMQOL-Proxy equated score 
(n=447) 
57.2 (9.0) 57.9 (10.7) 0.7 (-0.1 to 1.5) 
Dementia (n=286) 55.9 (8.7) 57.0 (10.8) 1.2 (0.1 to 2.2) 
MCI (n=107) 59.9 (9.0) 58.9 (10.0) -1.1 (-2.7 to 0.6) 
No diagnosis (n=36) 60.6 (9.0) 62.7 (11.8) 2.1 (-1.2 to 5.3) 
EQ-5D-3L Proxy index score 
(n=416) 
0.63 (0.30) 0.60 (0.31) -0.03 (-.05 to .006) 
Dementia (n=264) 0.62 (0.30) 0.59 (0.31) -0.03 (-.06 to .005) 
MCI (n=101) 0.67 (0.28) 0.62 (0.29) -0.05 (-0.1 to -.008) 
No diagnosis (n=33) 0.58 (0.34) 0.56 (0.34) -0.02 (-0.1 to .07) 
MCI – mild cognitive impairment. Numbers in bold indicate statistically significant difference 
between baseline and 12 month scores, p<0.05. 
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Table 3: Change in self- and proxy-reported health-related quality of life by patient characteristics 
Patient characteristics DEMQOL  DEMQOL-Proxy  
 N Change (SD) in 
score over 12 
months 
Adjusted difference 
in change * (95% CI 
with Bonferroni 
correction) (n=670) 
P-
value 
N Change (SD) in 
score over 12 
months 
Adjusted difference 
in change * (95% CI 
with Bonferroni 
correction) (n=435) 
P-
value 
Ages (years)         
     <75 231 4.0 (10.0) Reference  142 1.2 (8.7) Reference  
     75-79 158 3.4 (10.8) -0.7 (-3.6 to 2.2) 0.46 111 0.7 (8.4) -0.7 (-3.8 to 2.3) 0.48 
     80-84 163 2.5 (9.6) -1.0 (-4.0 to 1.9) 0.30 105 -0.7 (8.5) -1.6 (-5.3 to 2.1) 0.21 
     ≥85 142 3.8 (11.9) 0.2 (-3.4 to 3.8) 0.86 89 1.6 (10.0) -0.3 (-4.1 to 3.5) 0.82 
Sex         
     Male 359 2.7 (9.9) Reference  259 0.8 (9.0) Reference  
     Female 335 4.3 (11.0) 1.9 (-0.2 to 4.0) 0.01 188 0.6 (8.6) -0.7 (-3.7 to 2.2) 0.45 
Ethnicity         
     White/White British 658 3.6 (10.5) Reference  431 0.6 (8.8) Reference  
     Other ethnicity 33 2.5 (11.8) -1.9 (-6.7 to 2.9) 0.24 16 4.6 (10.4) 3.2 (-4.2 to 10.7) 0.20 
Deprivation          
     1 – least deprived 182 2.2 (9.6) Reference  130 0.2 (7.7) Reference  
     2 161 3.9 (10.4) 0.9 (-2.9 to 4.6) 0.50 105 0.01 (7.6) -0.5 (-3.9 to 2.9) 0.63 
     3 129 4.0 (10.9) 1.2 (-1.5 to 3.9) 0.20 81 1.0 (8.9) 1.0 (-3.0 to 5.0) 0.46 
     4 122 4.1 (10.6) 0.8 (-1.8 to 3.5) 0.35 71 2.0 (10.7) 1.4 (-3.1 to 5.9) 0.37 
     5 – most deprived 92 3.3 (11.3) 1.0 (-2.8 to 4.9) 0.43 54 0.7 (10.8) -0.4 (-4.4 to 3.6) 0.78 
Number of comorbidities         
     None 148 3.3 (11.3) Reference  89 0.7 (9.5) Reference  
     1 198 3.7 (11.1) 0.4 (-2.8 to 3.5) 0.74 129 0.9 (8.3) -0.4 (-4.2 to 3.3) 0.72 
     2 155 3.8 (10.6) 0.5 (-3.3 to 4.3) 0.69 107 -0.2 (9.3) -0.7 (-4.7 to 3.2) 0.58 
     3 or more 192 3.2 (9.1) -0.8 (-4.3 to 2.7) 0.48 122 1.4 (8.6) -0.1 (-3.8 to 3.6) 0.91 
* Adjusted for age, sex, ethnicity, deprivation, number of comorbidities, diagnosis, HRQL score at baseline and clustering by clinic. Bonferroni-corrected 
95% confidence intervals (family-wise error rate of 0.05 for each model divided by number of tests, p=0.004).  
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Table 4: Change in health-related quality of life at 12 months among patients with dementia diagnosis, by post-diagnostic interventions received 
(random effects model) 
 DEMQOL DEMQOL-Proxy  
 N Change (SD) in 
equated score over 
12 months 
Adjusted difference 
in change * (95% CI) 
P-
value 
N Change (SD) in 
equated score 
over 12 months 
Adjusted difference 
in change * (95% CI) 
P-value 
Anti-dementia drugs         
     No 107 3.4 (12.1) Reference  102 0.7 (9.1) Reference  
     Yes 183 6.0 (10.5) 3.7 (-0.1 to 7.5) 0.06 179 1.4 (8.5) 1.2 (-1.3 to 3.8) 0.34 
Psychosocial 
interventions 
        
     No 198 4.3 (11.2) Reference  192 0.6 (8.6) Reference  
     Yes 97 6.6 (11.1) 1.4 (-1.5 to 4.3) 0.34 93 2.0 (8.8) 1.6 (-1.0 to 4.1) 0.22 
         
* Adjusted for age, sex, ethnicity, deprivation, number of comorbidities, cognitive function, HRQL score at baseline and clinic as a random effect 
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Table 5: Differences in mean patient health-related quality of life scores at 12 months by MAS characteristics, in all participants and those with 
diagnosed dementia 
MAS characteristics Adjusted mean difference in patient HRQL score (95% CI with Bonferroni correction) and p-value 
All participants Participants with diagnosed dementia 
Structural characteristics DEMQOL (n=655) DEMQOL-Proxy (n=417) DEMQOL (n=381) DEMQOL-Proxy (n=267) 
Psychologists -0.3 (-3.6 to 2.9) 0.76 -1.4 (-5.2 to 2.4) 0.29 -0.9 (-5.3 to 3.5) 0.55 -0.6 (-4.6 to 3.4) 0.65 
Allied Health Professionals 1.3 (-2.4 to 5.0) 0.30 0.3 (-4.5 to 5.0) 0.86 0.7 (-3.4 to 4.8) 0.62 0.8 (04.7 to 6.2) 0.68 
Advisory & Support staff 2.2 (-1.1 to 5.5) 0.04 2.7 (-1.4 to 6.7) 0.05 4.3 (0.9 to 7.8) * <0.001 2.0 (-3.0 to 7.1) 0.23 
New patients per WTE staff per month 
(Reference: 1-3) 
        
     4-6 1.5 (-2.1 to 5.0) 0.21 1.9 (-3.1 to 6.8) 0.26 1.5 (-2.9 to 5.8) 0.32 1.2 (-4.3 to 6.8) 0.51 
     7 or more 0.07 (-3.6 to 3.8) 0.96 2.7 (-1.9 to 7.4) 0.08 1.2 (-3.3 to 5.6) 0.44 3.0 (-2.4 to 8.5) 0.10 
New patients seen per month (Reference: <25)         
     25-49 0.6 (-3.1 to 4.3) 0.64 0.3 (-4.4 to 5.0) 0.86 0.2 (-5.1 to 5.5) 0.92 -0.5 (-6.5 to 5.5) 0.81 
     50-74 -0.1 (-4.1 to 3.8) 0.93 -0.7 (-6.1 to 4.6) 0.69 -1.0 (-6.1 to 4.1) 0.56 -2.5 (-9.3 to 4.4) 0.29 
     75 or more 0.2 (-4.4 to 4.8) 0.89 -1.0 (-6.0 to 4.1) 0.58 -1.4 (-7.1 to 4.4) 0.47 -1.8 (-8.0 to 4.5) 0.40 
ECG offered at first appointment 0.4 (-3.2 to 4.0) 0.74 0.07 (-3.7 to 3.8) 0.96 0.3 (-4.0 to 4.6) 0.85 2.4 (-1.7 to 6.4) 0.08 
Neurological examination offered at first 
appointment 
-1.1 (-4.8 to 2.5) 0.36 0.7 (-3.2 to 4.6) 0.57 -1.1 (-5.7 to 3.5) 0.47 -0.4 (-4.8 to 4.1) 0.81 
Physical examination offered at follow up -0.08 (-4.0 to 3.9) 0.95 -2.1 (-7.6 to 3.3) 0.25 -0.4 (-4.7 to 3.9) 0.79 -1.7 (-8.3 to 5.0) 0.46 
Vision/hearing/mobility assessment offered at 
follow up 
-0.6 (-4.0 to 2.7) 0.93 2.0 (-3.0 to 7.1) 0.23 -0.3 (-4.9 to 4.2) 0.83 1.3 (-5.3 to 7.8) 0.56 
Provision of psychosocial support -0.6 (-4.0 to 2.7) 0.58 1.9 (-2.8 to 6.6) 0.23 0.05 (-3.7 to 3.8) 0.97 1.2 (-3.4 to 5.8) 0.45 
Process characteristics         
Waiting time to first appointment >6 weeks -1.2 (-4.4 to 2.0) 0.26 -2.3 (-7.4 to 2.8) 0.18 -1.5 (-5.4 to 2.4) 0.26 0.008 (-6.4 to 
6.4) 
0.99 
Length of first appointment (Reference: ≤60 
mins) 
        
     61-90 mins -0.4 (-3.2 to 2.4) 0.68 -0.7 (-4.5 to 3.1) 0.58 -1.3 (-4.8 to 2.1) 0.35 -0.3 (-5.1 to 4.5) 0.85 
     >90 mins 1.1 (-2.3 to 4.5) 0.35 -0.5 (-5.1 to 4.2) 0.76 2.3 (-1.8 to 6.4) 0.10 -0.9 (-6.4 to 4.5) 0.61 
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Two or more follow up appointments (Reference: 
≤1) 
1.3 (-2.1 to 4.6) 0.26 -2.2 (-7.1 to 2.7) 0.18 1.7 (-1.9 to 5.3) 0.16 -0.6 (-6.6 to 5.5) 0.77 
ECG – electrocardiogram; MAS – memory assessment service; WTE – whole time equivalent. Adjusted differences and Bonferroni-corrected 95% confidence 
intervals (family-wise error rate of 0.05 for each model divided by number of tests, p=0.003). Higher score indicates better health-related quality of life, 
HRQL. Adjusted for all structural and process characteristics, HRQL score at baseline, patient age, sex, ethnicity, deprivation, comorbidity, diagnosis and 
MAS as a random effect. * Statistically significant at family-wise error rate <0.05. 
 
